Established in December 2000, WuXi AppTec provides a broad portfolio of R&D and manufacturing services that enable companies in the pharmaceutical, biotech and medical device industries worldwide to advance discoveries and deliver groundbreaking treatments to patients. With industry-leading capabilities such as R&D and manufacturing for small molecule drugs, cell and gene therapies, and testing for medical devices, WuXi AppTec's open-access platform is enabling more than 3,700 collaborators from over 30 countries to improve the health of those in need – and to realize our vision that "every drug can be made and every disease can be treated".
Enabling more than 3,700 Innovative Collaborators from more than 30 Countries
Small Molecule Drug R&D and Manufacturing
Cell Therapy
and Gene Therapy
Drug R&D and Medical
Device Testing
Clinical
Services
Small Molecule Drug R&D and Manufacturing
To Become the Most Comprehensive Capability and Technology Platform in the Global Pharmaceutical and Healthcare Industry
Dr. Ge Li Awarded “CEO of the Year” at CPhI Worldwide 2019
WuXi AppTec Receives Investment Grade Corporate Ratings from Three Global Rating Agencies
WuXi AppTec Reports Third-Quarter 2019 Results
WuXi STA's Jinshan Facility Passes EMA Inspection
WuXi AppTec Research Service Division and BioSolveIT Introduce GalaXi®, a Vast New Chemical Space of Tangible Molecules
WuXi AppTec Launches DNA Encoded Library (DEL) Service Package “DELight” to Expedite Early Drug Discovery
